JP4976851B2 - 脂質レベルを哺乳動物において低下させる方法 - Google Patents

脂質レベルを哺乳動物において低下させる方法 Download PDF

Info

Publication number
JP4976851B2
JP4976851B2 JP2006538169A JP2006538169A JP4976851B2 JP 4976851 B2 JP4976851 B2 JP 4976851B2 JP 2006538169 A JP2006538169 A JP 2006538169A JP 2006538169 A JP2006538169 A JP 2006538169A JP 4976851 B2 JP4976851 B2 JP 4976851B2
Authority
JP
Japan
Prior art keywords
diabetic
age
rats
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509946A (ja
JP2007509946A5 (enExample
Inventor
ラーバー，サミュエル
フィガロラ，ジェームズ・レスター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2007509946A publication Critical patent/JP2007509946A/ja
Publication of JP2007509946A5 publication Critical patent/JP2007509946A5/ja
Application granted granted Critical
Publication of JP4976851B2 publication Critical patent/JP4976851B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2006538169A 2003-10-27 2004-10-27 脂質レベルを哺乳動物において低下させる方法 Expired - Fee Related JP4976851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51447603P 2003-10-27 2003-10-27
US60/514,476 2003-10-27
PCT/US2004/035440 WO2005044251A2 (en) 2003-10-27 2004-10-27 Methods of lowering lipid levels in a mammal

Publications (3)

Publication Number Publication Date
JP2007509946A JP2007509946A (ja) 2007-04-19
JP2007509946A5 JP2007509946A5 (enExample) 2007-11-22
JP4976851B2 true JP4976851B2 (ja) 2012-07-18

Family

ID=34572758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538169A Expired - Fee Related JP4976851B2 (ja) 2003-10-27 2004-10-27 脂質レベルを哺乳動物において低下させる方法

Country Status (6)

Country Link
US (2) US7320988B2 (enExample)
EP (2) EP1682114A2 (enExample)
JP (1) JP4976851B2 (enExample)
AU (1) AU2004287434B2 (enExample)
CA (1) CA2543611A1 (enExample)
WO (1) WO2005044251A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682114A2 (en) * 2003-10-27 2006-07-26 City of Hope Methods of lowering lipid levels in a mammal
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
US8580854B2 (en) * 2005-11-09 2013-11-12 City Of Hope Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors
US8124655B2 (en) * 2007-06-15 2012-02-28 City Of Hope Use of LR-90 and LR-102 to overcome insulin resistance
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20230048576A1 (en) * 2019-03-19 2023-02-16 City Of Hope Compounds for the treatment of neuropathic pain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514476A (en) 1894-02-13 Minnow-bucket
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US5272176A (en) 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5100919A (en) 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
DE3410927A1 (de) 1984-03-24 1985-10-03 Hoechst Ag, 6230 Frankfurt Vollaromatische polyester, verfahren zu ihrer herstellung und entsprechende formkoerper
US4801610A (en) * 1984-05-21 1989-01-31 G. D. Searle & Co. Phenolic ester derivatives as elastase inhibitors
US4603144A (en) * 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
US5268500A (en) 1987-06-15 1993-12-07 Montefiore Medical Center Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4921997A (en) 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5093367A (en) 1988-06-15 1992-03-03 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5833700A (en) 1995-03-15 1998-11-10 Ethicon Endo-Surgery, Inc. Sterile occlusion fasteners and instrument and method for their placement
WO1995031192A1 (en) 1994-05-16 1995-11-23 Thomas Jefferson University Method and use of agents to inhibit protein polymerization and methods of identifying these agents
US5661139A (en) 1995-01-13 1997-08-26 Alteon Inc. Bis-(2-aryl) hydrazones
US5962651A (en) 1995-01-27 1999-10-05 Montefiore Medical Center Modified hemoglobin and its use as a component of an artificial blood substitute
US5602277A (en) 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5667330A (en) 1995-11-28 1997-09-16 Case Corporation Quick-connect mechanism for releasably retaining a power take-off shaft within an output shaft hub
US5716987A (en) 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation
JP3864050B2 (ja) * 1998-10-22 2006-12-27 ユニヴァースティ オブ サウス カロライナ 糖尿病合併症を治療または予防するための医薬組成物
US6787566B2 (en) 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
ATE260099T1 (de) * 1999-04-05 2004-03-15 Hope City Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
US6605642B2 (en) 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US7030133B2 (en) 1999-04-05 2006-04-18 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
CA2371391A1 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
JP2003516328A (ja) 1999-12-13 2003-05-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞死疾患および炎症を治療するための方法
FR2836474B1 (fr) 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
EP1682114A2 (en) * 2003-10-27 2006-07-26 City of Hope Methods of lowering lipid levels in a mammal

Also Published As

Publication number Publication date
US20050171150A1 (en) 2005-08-04
WO2005044251A3 (en) 2005-08-25
EP1682114A2 (en) 2006-07-26
US20080200502A1 (en) 2008-08-21
AU2004287434A1 (en) 2005-05-19
US7320988B2 (en) 2008-01-22
EP2269601A1 (en) 2011-01-05
CA2543611A1 (en) 2005-05-19
US7652037B2 (en) 2010-01-26
AU2004287434B2 (en) 2011-04-07
JP2007509946A (ja) 2007-04-19
WO2005044251A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
US7652037B2 (en) Methods of lowering lipid levels in a mammal
Sourris et al. Inhibitors of advanced glycation end product (AGE) formation and accumulation
Pérez-Torres et al. Beneficial effects of the amino acid glycine
Javrushyan et al. Antihyperglycemic activity of L-norvaline and L-arginine in high-fat diet and streptozotocin-treated male rats
Noiri et al. Oxidative and nitrosative stress in acute renal ischemia
Smit et al. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation
CA2439791C (en) Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
Mihm et al. Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage
JP4860906B2 (ja) 心疾患および／または関連心不全の予防および／または治療
Abd-Elhamid et al. Reno-protective effects of ursodeoxycholic acid against gentamicin-induced nephrotoxicity through modulation of NF-κB, eNOS and caspase-3 expressions
Buehler et al. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
Joshi et al. Calcineurin regulates myocardial function during acute endotoxemia
Ott et al. Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade
JP2005533003A5 (enExample)
Hamdy et al. Modulatory effects of curcumin and green tea extract against experimentally induced pulmonary fibrosis: a comparison with N‐acetyl cysteine
Dinc et al. Methylene blue prevents surgery-induced peritoneal adhesions but impairs the early phase of anastomotic wound healing
JP2024544528A (ja) 肝障害の治療に使用するためのｓｓａｏ阻害剤及びｔｈｒ－ベータアゴニストの組合せ
Kostoglou-Athanassiou et al. Oxytocin release is inhibited by the generation of carbon monoxide from the rat hypothalamus–further evidence for carbon monoxide as a neuromodulator
JP3864050B2 (ja) 糖尿病合併症を治療または予防するための医薬組成物
Noa et al. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery
Nagareddy et al. N-acetylcysteine prevents nitrosative stress-associated depression of blood pressure and heart rate in streptozotocin diabetic rats
Jung et al. Ethyl pyruvate prevents renal damage induced by methylglyoxal‐derived advanced glycation end products
Ali et al. Aged garlic extract preserves beta-cell functioning via modulation of nuclear factor kappa-B (NF-κB)/Toll-like receptor (TLR)-4 and sarco endoplasmic reticulum calcium ATPase (SERCA)/Ca2+ in diabetes mellitus
Oziol et al. Inhibition of in vitro macrophage-induced low density lipoprotein oxidation by thyroid compounds
WO2000066101A2 (en) Method of inhibiting glycation product formation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110609

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120413

R150 Certificate of patent or registration of utility model

Ref document number: 4976851

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150420

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees